Cognivo Bridge turns a 3-minute smartphone recording into continuous neurodegenerative disease monitoring - delivered to your nurse portal every day. No wearables. No clinic visit required.
The patient records at home. Our AI extracts the biomarkers. You get a clinical PDF report. It takes under 3 minutes.
3 voice tasks on their smartphone: sustained "ahhh," rapid "pa-ta-ka," and reading a short passage aloud.
→The app verifies audio quality in real time (SNR > 18dB) and prompts a retry if the recording is too short or noisy.
→Our scoring engine extracts up to 15 acoustic biomarkers, classifies dysarthria subtypes, and computes zone scores within seconds.
→A 2-page PDF clinical report with biomarker trends, triage status, and clinical interpretation lands in your nurse portal.
Each task stresses a different dimension of neuromotor speech function. Together, they give you a window into motor control, vocal fold health, and cognitive-linguistic processing.
The patient holds a steady "ahhh" for 8 seconds. This isolates vocal fold vibration - the gold standard task in voice laboratories worldwide. Any instability comes directly from the neuromuscular control of the larynx.
FFTR frequency classifies tremor subtype without a clinic visit. CPP catches bulbar ALS onset before you can hear it. AVQI trended over weeks shows whether voice quality is stable, improving, or declining.
The diadochokinetic (DDK) task: "pa" tests the lips, "ta" the tongue tip, "ka" the tongue back. Together they exercise the entire oral motor system. When corticobulbar pathways or basal ganglia timing degrade, DDK reveals it.
When a PD patient's DDK rate is 5.2 at 9 AM but 4.3 at 4 PM, that 17% afternoon decline quantifies levodopa wearing-off. You can adjust medication timing based on objective motor data - not subjective patient recall.
The patient reads a standardized passage aloud. Unlike the first two tasks, reading loads the full system: respiration, phonation, articulation, and cognitive-linguistic processing simultaneously. Subtle cognitive deficits that are invisible during "ahhh" or "pa-ta-ka" become measurable here.
Rate ratio > 0.90 = motor-dominant slowness. Rate ratio < 0.70 = cognitive-dominant (word-finding pauses). This distinction guides whether you adjust motor medications or screen for cognitive decline. No other voice platform makes this differentiation.
Cognivo Bridge has the broadest disease coverage of any voice biomarker platform in neurology - verified against our production scoring engine.
Tremor classification (4-7Hz), DDK bradykinesia, medication wearing-off via diurnal variance, monotone pitch
Vocal tremor at 4-12Hz, FTRI severity, frequency-based differentiation from PD
Intention tremor 3-5Hz, scanning rhythm, excessive pitch variation, tighter DDK thresholds
Pause ratio elevation, word-finding failures, rate ratio cognitive decline, max pause duration tracking
Flaccid dysarthria pattern, CPP trajectory for bulbar onset, DDK rate decline slope
Spastic dysarthria pattern, relapse/remission fluctuation, fatigue-induced PM decline
Voice breaks, strained quality, treatment response tracking (Botox), AVQI monitoring
Hyperkinetic irregularity, choreiform timing disruption, variable DDK rate pattern
Steeper speech decline than PD, combined motor + cognitive involvement in reading
Every session is automatically classified based on the patient's biomarker trajectory relative to their personal baseline.
Building personal baseline (first 7 sessions). No alerts - data collection phase.
All biomarkers within personal baseline. Continue monitoring. Next scheduled visit.
Emerging deviation from baseline. Review PDF report. Schedule review within 2 weeks.
Sustained multi-zone decline. Motor, cognitive, or global. Urgent clinical review.
Every patient recording session counts as a billable RTM monitoring day. CMS pays your practice for the monitoring service. Cognivo Bridge provides the platform, the data, and the documentation.
| CPT Code | Description | Reimbursement |
|---|---|---|
| 98975 | RTM initial setup & patient education (one-time) | ~$19 |
| 98977 | RTM device supply, 16+ days per 30-day period | ~$52/month |
| 98980 | RTM treatment management, first 20 min/month | ~$50/month |
| 98981 | Each additional 20 min review (complex patients) | ~$41/add'l |
RTM codes (98975-98981) cover non-physiological data including voice and speech biomarkers. Distinct from RPM codes (99453-99458). Always verify current CMS rates with your billing department.
Nurse portal tracks billable days automatically. Compliance ring on every PDF shows proximity to 16-day threshold.
The vocal biomarkers market is $4B and growing at 18.8% CAGR. Cognivo Bridge is the only platform built for the practicing neurologist - not for pharma trials, not for enterprise wellness.
Global vocal biomarkers market (2025), growing at 18.8% CAGR to $10B+ by 2030.
~6,000-8,000 neurology practices. 400 clinics at 25 patients each = 10,000 patients = $12.2M ARR.
Monthly recurring RTM revenue. Predictable, CMS-backed, scales linearly with patient enrollment.
Most comprehensive voice biomarker panel in neurology. 3-task protocol with dysarthria subtyping and tremor classification.
Broadest neurodegenerative disease coverage of any voice platform. PD, ET, Cerebellar, Alzheimer's, ALS, MS, and more.
iOS TestFlight live. Backend deployed. Nurse portal operational. Clinical validation protocol designed with ICC targets >0.75.
"Our mission transcends technology. We're building bridges between human potential and artificial intelligence, creating pathways for cognitive healing that honor both the complexity of the brain and the dignity of the human spirit."
Cognivo Manora Inc. is headquartered in Fremont, California. We are building Cognivo Bridge - a voice biomarker platform purpose-built for the practicing neurologist who needs continuous, objective monitoring of their neurodegenerative disease patients between clinic visits.
Request a personalized demo and we'll walk you through the full platform - from patient recording to nurse portal to clinical PDF report.